Invention Grant
- Patent Title: Monoclonal antibody capable of binding integrin alpha 10 beta 1
-
Application No.: US15156032Application Date: 2016-05-16
-
Publication No.: US10087253B2Publication Date: 2018-10-02
- Inventor: Evy Lundgren-Akerlund
- Applicant: Xintela AB
- Applicant Address: SE Lund
- Assignee: Xintela AB
- Current Assignee: Xintela AB
- Current Assignee Address: SE Lund
- Agency: McNeill Baur PLLC
- Priority: SE0301087 20030414
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/46 ; C07K16/28 ; C12P21/08 ; G01N33/569 ; C12N7/00 ; C12N15/86

Abstract:
The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.
Public/Granted literature
- US20160319023A1 MONOCLONAL ANTIBODY CAPABLE OF BINDING INTEGRIN ALPHA 10 BETA 1 Public/Granted day:2016-11-03
Information query